English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

© 2010 The Authors. doi: 10.2340/00015555-0827 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 Psoriasiform drug eruptions can be induced by several drugs (1). Psoriasis is a chronic inflammatory disease characterized by T-cell-mediated cytokine production that drives the hyperproliferation and abnormal differentiation of keratinocytes (2). Drugs can cause new lesions when there is no history or family history of psoriasis. Based on the psoriatic drug eruption probability score, β‐blockers, synthetic anti‐malaria drugs, non‐steroidal anti‐inflammatory drugs (NSAIDs), lithium, digoxin, and tetracycline antibiotics are relevant in psoriasis (1, 3–5). Common cutaneous adverse effects of anti-tuberculosis medication include morbilliform rash, urticaria, lichenoid drug eruption, exfoliative dermatitis, hyperpigmentation, erythema multiforme-type drug eruption and Stevens-Johnson syndrome (6–8). We report here the first case of a psoriasiform drug eruption in a man taking anti-tuberculosis medication.

Psoriasiform Drug Eruption Induced by Anti-tuberculosis Medication: Potential Role of Plasma­cytoid Dendritic Cells

Psoriasiform Drug Eruption Induced by Anti-tuberculosis Medication: Potential Role of Plasmacytoid Dendritic Cells